Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 6,251–6,275 of 27,380 studies, newest first · page 251 of 1096.

August 2024 25

  1. 2024-08-30

    IRF3 regulates neuroinflammatory responses and the expression of genes associated with Alzheimer's disease

    ✓ Peer-reviewed Inflammation and the immune system Journal of neuroinflammation

    Key finding: Moreover, expression of a constitutively active IRF3 (S388D/S390D: IRF3-2D) in microglia induces a transcriptional program reminiscent of the Activated Response Microglia and the expression of genes associated with Alzheimer's disease, notably apolipoprotein-e. +1 more finding

  2. 2024-08-30

    Association between air pollution and cerebrospinal fluid alpha-synuclein in urban elders: the CABLE study

    ✓ Peer-reviewed Risk factors Frontiers in aging neuroscience

    Key finding: We found a significant correlation of CSF α-syn level with PM2.5 in urban participants. +3 more findings

  3. 2024-08-30

    The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice

    ✓ Peer-reviewed Drug development Molecular metabolism

    Key finding: Semaglutide reduced body weight and improved glucose tolerance in 12-month-old male and female 5XFAD and APP/PS1 mice, consistent with pharmacological engagement of the GLP-1R. +4 more findings

  4. 2024-08-30

    Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab

    ✓ Peer-reviewed Treatments Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Our case suggests that ischemic strokes may be a feature of ARIA and highlights the importance of having a high clinical suspicion for seizures in ARIA. +4 more findings

  5. 2024-08-29
  6. 2024-08-29

    Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease

    ✓ Peer-reviewed Treatments CPT: pharmacometrics & systems pharmacology

    Key finding: Importantly, age, a well-recognized risk factor for AD, was not found to significantly affect lecanemab PK. +2 more findings

  7. 2024-08-29

    Parallel electrophysiological abnormalities due to COVID-19 infection and to Alzheimer's disease and related dementia

    ✓ Peer-reviewed Inflammation and the immune system Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: EEG abnormalities have the potential as neural biomarkers to identify neurological complications at the early stage of the disease, to assist clinical assessment, and to assess cognitive decline risk in Long COVID patients. +4 more findings

  8. 2024-08-29

    CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders

    ✓ Peer-reviewed Biomarkers Neurology

    Key finding: We tested the CSF of 40 patients with CBS (19 female patients, 65.9 ± 8.6 years) and 28 with PSP (13 female patients, 72.5 ± 8.7 years old), mostly White (n = 50) or Asian (n = 14). αSyn-SAA positivity was observed in 35.9% patients with CBS and 28.6% with PSP. +2 more findings

  9. 2024-08-28

    APOE4-related differences in cortical thickness are modulated by sex in middle age

    ✓ Peer-reviewed Genetics Brain imaging and behavior

    Key finding: Compared to males, females had thicker superior frontal cortices bilaterally, left middle temporal cortex, and left pars triangularis. +4 more findings

  10. 2024-08-28

    Cellular communities reveal trajectories of brain ageing and Alzheimer's disease

    ✓ Peer-reviewed Inflammation and the immune system Nature

    Key finding: Here we used a data-driven approach to reconstruct the dynamics of the brain's cellular environment and identified a trajectory leading to AD that is distinct from other ageing-related effects. +3 more findings

  11. 2024-08-27

    Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study

    ✓ Peer-reviewed Drug development Annals of internal medicine

    Key finding: Overall, 12 489 patients initiating SGLT2 inhibitor treatment (51.9% dapagliflozin and 48.1% empagliflozin) and 1075 patients initiating dulaglutide treatment were included. +4 more findings

  12. 2024-08-26

    Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease

    ✓ Peer-reviewed Inflammation and the immune system Cells

    Key finding: Most clinical trials targeting the classical hallmarks of this disease-β-amyloid plaques and neurofibrillary tangles-failed, showed discrete clinical effects, or were accompanied by concerning side effects. +4 more findings

  13. 2024-08-26

    Global Public Health Implications of Traffic Related Air Pollution: Systematic Review

    ✓ Peer-reviewed Risk factors Environmental health insights

    Key finding: In this study, 1 282 032 participants ranging from 19 to 452 735 were included in 30 articles published from 2010 to 2022. +4 more findings

  14. 2024-08-26

    The association between sleep and Alzheimer's disease: a systematic review

    ✓ Peer-reviewed Risk factors Dementia & neuropsychologia

    Key finding: Studies suggest that individuals who experience memory loss may encounter sleep disturbances before noticing other symptoms. +4 more findings

  15. 2024-08-26

    Color Fundus Photography and Deep Learning Applications in Alzheimer Disease

    ✓ Peer-reviewed Brain scans and imaging Mayo Clinic proceedings. Digital health

    Key finding: The self-supervised ADRET model had superior accuracy when compared with ADVAS, in both UK Biobank (98.27% vs 77.20%; P<.001) and our institutional testing data sets (98.90% vs 94.17%; P=.04). +4 more findings

  16. 2024-08-26

    Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations

    ✓ Peer-reviewed Disparities Nature medicine

    Key finding: LAC models evidenced older brain ages (functional magnetic resonance imaging: mean directional error = 5.60, root mean square error (r.m.s.e.) = 11.91; electroencephalography: mean directional error = 5.34, r.m.s.e. = 9.82) associated with frontoposterior networks compared with non-LAC models. +3 more findings

  17. 2024-08-25

    Improving genetic risk modeling of dementia from real-world data in underrepresented populations

    ✓ Peer-reviewed Disparities Communications biology

    Key finding: Genetic risk modeling for dementia offers significant benefits, but studies based on real-world data, particularly for underrepresented populations, are limited. +2 more findings

  18. 2024-08-23

    Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

    ✓ Peer-reviewed Treatments Signal transduction and targeted therapy

    Key finding: Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant and escalating global challenges.

  19. 2024-08-23

    Geographic disparities in Alzheimer's disease and related dementia mortality in the US: Comparing impacts of place of birth and place of residence

    ✓ Peer-reviewed Risk factors SSM - Population Health

    Key finding: We found that both state of birth and state of residence account for a modest portion of ADRD mortality variation. +4 more findings

  20. 2024-08-23

    Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies

    ✓ Peer-reviewed Inflammation and the immune system Science (New York, N.Y.)

    Key finding: We report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN), rescues hippocampal memory function in mouse preclinical models of AD by restoring astrocyte metabolism. +3 more findings

  21. 2024-08-23
  22. 2024-08-22
  23. 2024-08-22
  24. 2024-08-22

    Digital Cognitive Test for Early Detection of Dementia

    ✓ Peer-reviewed Cognitive tests and assessment Studies in health technology and informatics

    Key finding: Dementia poses a significant global health problem, necessitating early detection for effective intervention.

  25. 2024-08-22

Browse the library by subject, with the full score breakdown →